# Aptadir secures €40 million seed round for RNA therapies

_Published Tuesday, September 29, 2026 at 10:20 AM EDT · Capital · Latest · Tier 2 — Notable_

![Aptadir secures €40 million seed round for RNA therapies — Primary](https://media.zawya.com/prod/images/gm_preview/b4ce7915e88d-aptadir-therapeutics-image.png)

Aptadir Therapeutics secured a €40 million seed round that includes an investment from CE-Ventures, the venture arm of Crescent Enterprises, CE-Ventures announced Tuesday. The financing will support the preclinical company's work on RNA-based treatments for genetic disorders and oncology, including its lead candidate for Fragile X syndrome.

Aptadir's experimental molecules are designed to interfere with abnormal DNA methylation, a process that can silence genes. The company says it has demonstrated gene reactivation in patient-derived disease models. The round gives Aptadir capital to advance its pipeline toward clinical development, but its lead treatment remains preclinical.

## Sources

- [zawya.com](https://www.zawya.com/en/press-release/companies-news/ce-ventures-backs-aptadir-therapeutics-in-40mln-seed-round-one-of-europes-largest-in-biotech-1422579)

---
Canonical: https://techandbusiness.org/newswire/8M62jrtGiUqt_CLn5VLc3O
Published: 2026-09-29T14:20:28.308Z
Story chronology: 2026-09-29T12:42:59.551Z
Retrieved: 2026-09-29T16:13:46.738Z
Publisher: Tech & Business (techandbusiness.org)